Skip to main content

Table 3 Blood parameters

From: Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial

Parameters

Range

Day 0

Year 1

Year 2

Year 3

Year 4

Year 5

 

Group

 

(Mean ± SD)

     

White blood count

       
 

Placebo + Tamoxifen

4-11

6.29 ± 2.09

6.77 ± 1.79

7.06 ± 2.07

7.11 ± 2.37

7.22 ± 7.22

7.36 ± 7.36

 

TRF + Tamoxifen

(×109/L)

5.86 ± 2.01

5.81 ± 1.59

5.86 ± 1.78

6.28 ± 1.92

6.33 ± 1.76

6.46 ± 1.62

Red blood count

       
 

Placebo + Tamoxifen

3.8-5.8

4.48 ± 0.48

4.46 ± 0.44

4.41 ± 0.40

4.49 ± 0.46

4.43 ± 0.54

4.55 ± 0.53

 

TRF + Tamoxifen

(×1012/L)

3.95 ± 0.81

4.24 ± 0.41

4.27 ± 0.34

4.28 ± 0.34

4.27 ± 0.45

4.28 ± 0.40

Hemoglobin

       
 

Placebo + Tamoxifen

11.5-16.5

12.49 ± 1.28

12.40 ± 1.18

12.63 ± 1.16

12.66 ± 0.96

12.61 ± 0.92

12.70 ± 0.96

 

TRF + Tamoxifen

(g/dl)

11.79 ± 2.48

12.71 ± 1.13

12.67 ± 0.93

12.72 ± 0.99

12.65 ± 1.27

12.77 ± 1.01

Hematocrit

       
 

Placebo + Tamoxifen

37-47

38.90 ± 3.27

38.34 ± 2.56

38.53 ± 2.82

38.48 ± 2.68

37.44 ± 8.69

38.69 ± 3.06

 

TRF + Tamoxifen

(%)

35.51 ± 7.30

38.76 ± 4.31

37.96 ± 4.32

38.68 ± 2.97

38.36 ± 4.19

38.63 ± 3.27

Lymphocyte

       
 

Placebo + Tamoxifen

20-45

33.03 ± 6.62

33.37 ± 6.21

34.30 ± 8.13

35.19 ± 6.27

34.82 ± 8.32

35.48 ± 7.20

 

TRF + Tamoxifen

(%)

31.42 ± 8.35

33.79 ± 9.41

33.22 ± 8.58

34.65 ± 8.68

34.59 ± 6.63

36.39 ± 9.58

Platelet count

       
 

Placebo + Tamoxifen

150-400

221.52 ± 60.59

221.48 ± 46.09

222.19 ± 61.39

238.10 ± 61.63

250.00 ± 61.87

260.10 ± 57.85

 

TRF + Tamoxifen

(×109/L)

221.16 ± 89.81

217.89 ± 50.74

217.63 ± 58.52

226.13 ± 49.69

247.74 ± 76.05

243.07 ± 61.02

  1. The mean values of the results from the biochemical screening tests on day 0 and years 1, 2, 3, 4, and 5 of tocotrienol-rich fraction (TRF)-plus-tamoxifen supplemented group and placebo-plus-tamoxifen supplemented group.